The increasing number and complexity of medical devices with several functions prompted FDA to provide medical device manufacturers with premarket and postmarket regulatory guidance. In a nutshell, FDA states that it shall not regulate non-device functions of a product with multiple functions – but can consider the impact of non-device functions on the device functions. The guidance identifies the principles and premarket review practices, postmarket requirements, and multiple examples of the application of the policy.
The term “multiple function” device was first officially addressed by FDA in the 21st Century Cures Act Section 3060 that amended the Federal Food, Drug, and Cosmetic Act (FD&C Act). The guidance amended the definition of “device” removing certain software functions (medical and decision software support) and clarifies which software functions (analyze or interpret medical data) remain under FDA’s oversight.
The guidance document is intended to clarify FDA’s policy approach to all multiple function devices, considerations for the design and risks of multiple function device products, and impact assessment of non-device software functions or “other functions” on safety and effectiveness. Furthermore, the guidance provides recommendations on the premarket submission content FDA expects for a device function that is part of a multiple device product. Modifications and postmarket requirements are also addressed.
The policy is risk based with a functionally focused approach to software that is platform independent. The regulation is narrowly tailored to the device’s risk based on the function with the ultimate intent to protect patient safety.
In the guidance, FDA clearly delineates “other functions” and device function-under review.
Definitions
To begin, FDA defines function as a “distinct purpose of the product” and further clarifies that function could be the intended use or a subset of the intended use of the product. For example, a device with the intended use of storing, transferring, and analyzing data has three functions while a device with the intended use of analyzing data has only one.
“Other function” is considered a function that:
Does not meet the definition of device;
Meets the definition of device, but is not subject to premarket review (e.g., 510(k)-exempt); or
Meets the definition of device, but for which FDA has expressed its intent not to enforce compliance with applicable regulatory controls.
Multiple function devices are comprised of functions that are subject to FDA’s regulatory oversight and “other functions” that are not.
Device function-under review is defined as a function for which FDA is conducting premarket review.
Policy: Premarket Review Considerations for Multiple Function Device Products
The guidance clarifies that while “other functions” that are part of a multiple-function device are not the subject of FDA review, FDA may assess the impact of “other functions”when conducting the premarket review to determine the devices safety and effectiveness.
“Other Functions”Should be Separated in Design and Implementation
FDA considers the separation of functions of the device-under-review from “other functions” important for risk control. Ideally, the separation occurs early in the design with a higher degree of separation allowing for easier review of the independent safety and effectiveness of the devices function.
Making architecture decisions early in the design cycle that facilitate risk control especially allow for the evaluation of optimal separation and support segregation of:
Logic
Architecture
Code
Data partitioning
This separation is considered “especially important when considering cyber security risk and mitigations.”
Risk Analysis Needs to Considerthe Impact of Other Functions
The guidance outlines the following as critical for manufacturers to consider regarding the impact of other functions.
Role of the “other function” in the devices function-under-review’s performance;
Limitations of the device function-under-review when using the “other function:”
Developing appropriate hardware and software resources specifications(s) for the product with multiple functions to ensure minimal impact of the “other function” on the performance of the device functions-under-review;
How to ensure appropriate actions are taken by the end user when using the device function-under-review with the “other functions;” and
Identification, evaluation, and mitigation of any additional risks, including cybersecurity risks, in the device-functions-under-review when used in combination with the “other function.”
When separation cannot be achieved, the interconnectedness and interdependencies of the devices function and “other function” needs to be included in the hazard analysis. Furthermore, an appropriate control must be created.
Assessing the Impact of “Other Functions” on the Device Function-Under-Review
FDA is clear on how it intends to assess the impact of “other functions” and provides a flow chart to guide manufacturers through the assessment.
Manufacturers need to conduct a risk assessment to determine if the “other functions” impact the safety and effectiveness of the device under review. The other functions could act to have a positive effect or an adverse effect.
A two-step process summarizes the premarket assessment.
First, is there an impact on the Safety and Effectiveness of the device function-under review as a result of the “other function?” If yes, could this be a negative impact, meaning an increased risk or an adverse effect on performance of the device function under review?
Positive impact assessments must include the beneficial impact of “other functions” on the device-under-review when the device is operating as intended. In addition, the manufacturer must confirm that the “other functions” do not impart an adverse impact if the device-under-review fails to operate as intended.
Negative impact assessments must identify the potential for an increased risk and/or adverse effect on performance “due to the combination of the other function with the device-under-review.
“Other functions” that impact the device under review must be evaluated and included in the hazard analysis.
Manufacturers need only added other functions to the submission if the positive effects are represented on the device label – a labeled positive impact – or if it may negatively impact the device that is under review.
Examples of Multiple Function Devices
The FDA provides 7 examples of multiple function device products in Appendix 1. The examples provide a description of the product, product functions (see list below), description of the impact of the “other function” on the device function-under-review and an explanation of the impact assessment.
Below is a list of the hypothetical example device products. See the guidance for details on impact assessment.
Skin cancer detection software application
Device function under review:
Software app that detects skin cancer
“Other function:”
Smart phone computing platform
Camera on the computing platform
Hand-held coagulation device
Device function under review:
Hand help coagulation instrument
Coagulation (prothrombin time) test
“Other function:”
Docking station
Interface to transmit the data to the HIS
Traumatic brain injury determination
Device function under review:
Collection and recording of EEG signals
Analyzing EEG signals and diagnosing TBI
Presentation of results
“Other function:”
General use computing platform
Electronic administration of questionnaire
Pain treatment app
Device function under review:
Electronic Nerve Stimulation as a treatment for pain
App used to control the level of stimulation
“Other function:”
Mobil platform Bluetooth transceiver and connectivity
Transmission of vital sign measures to an Electronic Health Record (HER)
Device function under review:
Vital signs acquisition
“Other function:”
Transmission software for sending data to the HER system
Wi-Fi card
Energy-delivering device with optional app (MDDS)
Device function under review:
Energy-delivering aesthetic device
“Other function:”
Mobil app that integrates with device and transfers treatment parameter data (e.g., number of treatments, treatment parameters) to a cloud-based storage – no real-time transmission is allowed
Smart phone computing platform
Pulsed ultrasound and biopsy needle guide kit
Device function under review:
General purpose diagnostic ultrasound system
Biopsy needle tracking functionality
“Other function:”
510(k)-exempt needle guide kit
Postmarket Guidance
The guidance applies to post-market regulations and implicitly states that device functions must comply with design control requirements and expectations surrounding adverse event reporting.
FDA reinforced its position that it does not intend to “enforce general control requirements for device functions for which FDA has expressed its intention to not enforce applicable regulatory controls at this time.”
Multiple function device products that have undergone modifications of the “other function” must be assessed to determine if the change has the potential to significantly impact the safety or effectiveness of the device function that was the subject of FDA review.
This guidance document was written to clarify current regulations as well as to promote innovation and patient engagement with digital health products.
The generation of technical documents that are required for medical device premarket approval requires time and expertise. Consider increases in your company’s efficiencies by working with a team of medical writers that are document experts. At Criterion Edge, we take pride in teaming up with industry experts to provide high quality support. Please reach out to us for a free consult.
State of the Art: Building a Solid Foundation for your PER to Support IVDR Readiness
In this webinar, Dr. Sarah Chavez provides an overview of the State of the Art section, and explains how it fits into the overall process of writing a successful, IVDR-compliant Performance Evaluation Report (PER) in a reasonable time frame. A complete readiness assessment and gap analysis will help you identify critical resources, feeder documents, and expertise needed to establish that your IVD may be considered “state-of-the-art.” Ultimately, knowing what the Notified Body expects to see will help you avoid project delays and discover efficiencies in the SOA development process.
Leveraging the MDR experience for IVDR: Tips for Successful Performance Evaluation and PMS/PMPF Processes [Free Webinar]
Have the IVDR Performance Evaluation and Post Market Surveillance requirements got you tied up in knots? Where do you start? What does the end product look like? We are joined by the VP of Regulatory, Quality, and Clinical from Nextern, a collaborative medical device company bringing unmatched core competence in medical device product design and development. Criterion Edge’s President Laurie Mitchell will lead a discussion of their experiences supporting clients through MDR and IVDR requirements.
Effective Corporate Scientific Communication: Strategies to Support your Corporate Narrative and Maximize the Real-World Impact of your Data [Free Webinar]
In this practical presentation, President Laurie Mitchell will: 1) discuss how an effective scientific communication plan is an important marketing tool for an organization, and 2) present five strategies to ensure your corporate objectives are supported and maximize the real-world impact of your data. Join us to learn how this applies to your organization and how to implement these strategies into your current processes.
Hidden Traps That Derail PER Preparedness: Lessons Learned from the MDR-Compliant CER Writing Experience [Free Webinar]
In this practical presentation, Criterion Edge uncovers what we have learned from our experience in writing MDR-compliant CERs, and how urgently applicable some of these key learnings are in preparing a robust Performance Evaluation Report (PER).
Hidden Traps That Can Derail Your CER: Answer These Critical Questions Before You Start Writing [Free Webinar]
As we all know, the MDR has significantly increased both the quality and quantity of inputs needed to complete a CER, needing more up-front planning than the reports have in the past. Based on our experiences with clients both large and small, our President, Laurie Mitchell, shares some of the biggest issues we have discovered when starting an MDR CER project. Laurie also reveals some of the most successful strategies in addressing these issues, up-front and early.
A Practical Guide: Conducting Systematic Literature Reviews in Support of IVDR Readiness [Free Webinar]
In this practical presentation, Criterion Edge breaks down the steps of the SLR process and takes a wholistic approach to conducting an IVDR-compliant SLR. Using case studies, the presentation illustrates the effective use of SLR-derived data to develop the Scientific Validity Report (SVR) and the Clinical Performance Report (CPR).
How to Assess Your CER for MDR Readiness, Part 2 [Free Webinar]
In this second installment of our 2-part webinar series, Criterion Edge shares practical presentation to help you assess your CER through the critical lens of a writer and identify possible gaps for mitigation before prior to submission to regulatory authorities.
Systematic Literature Review: How to Empower Data-Driven Decision Making [Free Webinar]
In this webinar, we share the process of systematic literature review, and discuss the tools and best practices for creating a methodologically-sound systematic literature review.
Experience and Scalability
Watch this video to learn how Criterion Edge is different from the rest.
5 Key Questions to Help Manage Your Budget
This infographic goes through 5 key questions to go through in order to control your budget.
Examining the Implications of the MDR on Data Management
Leading industry experts come together to discuss how the MDR affects data management within their respective units.
MedDev 2.7/1 Guideline: Equivalence and Risk/Benefit Profile
This report clarifies the modifications to the equivalence guidelines in MEDDEV 2.7/1 and Quality Management Systems (QMS) ISO 13485 standard to help develop strategies.
MedDev 2.7/1 Guideline: Qualifications of Evaluators and Scientific Validity
This gap analysis addresses key revisions to evaluator qualifications and scientific validity in the Clinical Evaluation (CE) MEDDEV guideline rev.4.
MedDev 2.7/1 Guideline: More Clinical Evaluations?
The changes to 2.7/1 rev. 4 suggest the need to submit more frequent CERs to regulatory authorities, however, strategies will be discussed for managing the increased requirements.
Data Mining: New Initiatives on Health Care Data that Manufacturers Should be Watching
Every time a healthcare provider makes a notation in the medical chart, a significant and valuable piece of data has been created. This paper discusses the implications of this.
10 Strategies to Build Efficiencies in your Regulatory Writing Process
This piece discusses 10 key strategies to building an efficient regulatory writing process.
State of the Art: Best Practices and Literature Review Using DistillerSR
In this paper, we discuss a prominent clarification on the MEDDEV 2.7.1 rev 4, establishing the “state of the art” section.
Q&A Follow-Up: How to Assess Your CER for MDR Readiness, Part 1 [Free Webinar]
The overwhelming turnout at the ‘How to Assess Your CER for MDR Readiness, Part 1’ prompted us to host a live Q+A session where President Laurie Mitchell exclusively answers all your questions.
Systematic Literature Review To Help Meet MDR Requirements [Free Webinar]
President Laurie Mitchell returns to continue sharing more about the importance of the systematic literature review.
Systematic Literature Review: How to Empower Data-Driven Decision Making [Free Webinar]
In this webinar, we share the process of systematic literature review, and discuss the tools and best practices for creating a methodologically-sound systematic literature review.
State of the Art Literature Review for EU MDR Compliance: How To Get It Right [Free Webinar]
Establishing and defining state of the art for a medical device is no longer an isolated task – it supports the entire Clinical Evaluation Report (CER). Multiple sections of the MEDDEV 2.7/1 rev 4 compliant CER need to be supported by state of the art data, including safety and performance, risk management, and equivalence.
How to Assess Your CER for MDR Readiness, Part 1 [Free Webinar]
In this first installment of a 2-part webinar series, Criterion Edge will present strategies for assessing key components of your CER (or CER template) for possible misalignment with significant and applicable MDR requirements.
Intro to Adverse Event Reviews [Free Webinar]
In this webinar, President Laurie Mitchell discusses why safety reviews are essential in the entire life cycle of product development.
Advantages to Technologies Supporting Endpoint Adjudication [Free Webinar]
Kyoko Hattori from Criterion Edge returns to discuss best practices for managing the adjudication process in-house, and Brian Kelly from AG Mednet will share how the “JUDI” platform can simplify the management of adjudication.
Endpoint Adjudication by the Clinical Endpoints Committee (CEC) [Free Webinar]
In this webinar, learn about CECs, familiarization with regulatory guidance, decision factors leading to use of a CEC, and much more.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Tag Manager and Pardot's tracking features to collect information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!